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E-mail address: boazt@ekmd.huji.ac.il (B. Tirosh).B lymphocyte induced maturation protein-1 (Blimp-1) is a transcription repressor of the Krueppel-
like family. Blimp-1 plays important roles in developmental processes, such as of germ cells and hair
follicle stem cells. In B lymphocytes Blimp-1 orchestrates the terminal differentiation into plasma
cells.
We discovered that Blimp-1 undergoes SUMOylation by SUMO-1. This SUMOylation is modulated
by the SUMO protease SENP1. While Blimp-1 is relatively stable in 293T cells, a fusion with SUMO1
rendered it to rapid proteasomal degradation. Increase in SENP1 activity stabilized Blimp-1, while a
decrease promoted its degradation. Our data indicate that SUMOylation of Blimp-1 regulates its
intracellular stability.
Structured summary of protein interactions:
Blimp1 physically interacts with SUMO1 by anti tag coimmunoprecipitation (View Interaction 1, 2).
SUMO1 physically interacts with Blimp1 by anti tag coimmunoprecipitation (View interaction).
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction identity and proliferation. In fact, Blimp-1 is a critical tumor sup-B lymphocyte induced maturation protein-1 (Blimp-1) is a tran-
scriptional repressor with ﬁve Krueppel-type zinc ﬁngers [1].
When attached to DNA by virtue of its Zinc ﬁngers, transcriptional
repression of the target gene is achieved by recruitment of core-
pressors of the Groucho family [2], chromatin-modifying enzymes
such as histone H3 methyltransferase G9a [3] and histone deacet-
ylases (HDACs) [4].
Blimp-1 exerts diverse biological activities in different cellular
contexts. Primarily, it is essential for stemness characteristics of
various types of stem cells [5–7] and for the terminal differentia-
tion of B lymphocytes into antibody-secreting plasma cells [1]. In
the absence of Blimp-1 little Ig is secreted in response to both T
cell-independent and T cell-dependent antigens [8]. In this context,
Blimp-1 directly suppresses Pax5 [9] and Myc [10] and thereby
interferes with the expression of genes necessary for the B cellchemical Societies. Published by E
maturation protein-1; KLF,
eciﬁc protease; SUMO, small
armacy, The Hebrew Univer-
2 2 6758741.pressor in the B cell lineage [11,12]. Importantly, the levels of
Blimp-1 are a key for its biological activity. While plasmablasts ex-
press low levels of Blimp-1, establishment of mature long-lived
plasma cells (PCs) requires increased levels of Blimp-1 expression
[13]. Moreover, the continuous expression of Blimp-1 is critical
for the maintenance of PCs after full differentiation [14]. Therefore,
understanding the various mechanisms that control Blimp-1 levels
are of paramount importance.
Post-translational modiﬁcation of proteins with the small ubiq-
uitin-like molecule (SUMO) is a dynamic and fundamentally
important modiﬁcation, which plays a role in a range of biological
processes. Human and mouse genomes encode three functional
SUMO isoforms (SUMO-1, SUMO-2 and SUMO-3) and one isoform
that may not be processed to its mature form (SUMO-4). SUMO-1
differs signiﬁcantly in structure from SUMO-2 and SUMO-3, which
are very similar, and modiﬁes a distinct yet overlapping group of
proteins [15]. SUMOylation is reversible by a family of SUMO iso-
peptidases called SENPs.
Here,we showthatBlimp-1 is SUMOylatedbySUMO-1 soonafter
synthesis. The SUMOylation is reversible primarily by SENP1.While
Blimp-1 is stable in 293T HEK cells an N-terminal fusion to SUMO-1
renders it unstable. In other cell types Blimp-1 is turned over more
rapidly and its stability can be increased by the expression of SENP1lsevier B.V. All rights reserved.
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of Blimp-1 serves as a signal for its degradation.
2. Materials and methods
2.1. Cells, transfection and reagents
P3X cells were grown in RPMI medium supplemented with 10%
FCS (Hyclone, EU approved), 2 mM glutamine, 50 u/ml penicillin,
50 lM 2-mercaptoethanol and 50 lg/ml of streptomycin. 293T
and HeLa cells were maintained in DMEM supplemented with
10% FCS (Hyclone, EU approved), 2 mM glutamine, 50 l/ml penicil-
lin and 50 lg/ml of streptomycin. Cells were transfected using
standard calcium phosphate precipitation protocol. Expression
vectors for SENP-1 and SENP-1-DN (a catalytically inactive SENP1)
constructs were provided by Dr. Grace Gill (Tufts University, Bos-
ton, MA). Expression vector for C-terminal FLAG-tagged Blimp-1
was provided by Dr. Katherine Calame (Columbia University,
New-York, NY). Expression vectors for HA-tagged ubiquitin like
proteins were provided by Dr. Hidde Ploegh (Whitehead Institute,
Cambridge, MA). M2 anti-FLAG antibodies and beads were pur-
chased from Sigma. The hybridoma clone 12CA5 was used to detect
the HA epitope. Anti SUMO-1 antibody was purchased from Cell
Signaling Technology (C21A7). Endogenous Blimp-1 was detected
by two monoclonal antibodies: rat anti-Blimp-1, Santa Cruz, 6D3
and mouse anti-Blimp-1, Novus, 3H2-E8. Secondary HRP-conju-
gated antibodies were purchased from Jackson ImmunoResearch
Laboratories (West Grove, PA).
2.2. Retroviral transduction with SENP1 shRNA
Retroviral vectors containing mouse SENP1-speciﬁc shRNA tar-
gets were purchased from Open Biosystems. Retroviruses were
generated in 293T cells by triple transfection with Gag-Pol and
Env expressing vectors. Following retroviral transduction and
puromycin selection of P3X cells we selected clone V2MM_25105
as the most efﬁcient in knocking down SENP1 (see Fig. S1).
2.3. Pulse-chase analysis and immunoprecipitation
Metabolic labeling was performed after starvation in methio-
nine/cysteine-free Dulbecco’s modiﬁed Eagle’s medium (Biological
Industries Beit Haemek, Israel) for 45 min. Then, cellswere pulse-la-
beled with [35S]-methionine/cysteine (7.5 mCi/500 ll) (Amersham,
USA) at 37 C for the indicated time. Chase period was initiated by
addition of complete cell medium supplemented with a 50-fold ex-
cess of non-radiolabeled cystein/methionine. Cells were then lysed
in 1% SDS preheated to 70 C to avoid post-lysis deSUMOylation. Ly-
sates were subsequently diluted by addition of 1.5 ml lysis buffer
(Tris pH = 8 50 mM, NaCl 200 mM, MgCl2 20 mM and 1% NP-40,
3 ll/ml normal rabbit serum, 10 ll/ml 0.1% BSA and protease inhib-
itors). Non speciﬁc protein bindingwas removed by addition of pro-
tein A beads (ADAR BioTech, Israel). Immunoprecipitation was
performed using the indicated antibodies. Anti-FLAG immunopre-
cipitations were performed with anti-FLAG beads (A2220, Sigma).
Immunoprecipitates were washed four times in the lysis buffer that
contained 0.1% SDS, boiled in sample buffer and analyzed by SDS–
PAGE, followed by auto-radiography or Western blotting.
3. Results
3.1. Blimp-1. is reversibly modiﬁed by SUMO-1
When examined by immunoblot (rat anti-Blimp-1, Santa Cruz,
6D3) in the plasmacytoma cell line P3X, which endogenously
expresses Blimp-1, we noticed that Blimp-1 yields two distinctpolypeptides; one that migrated on SDS-PAGE at the expected size
(100 Kd) and an additional polypeptide that was slightly heavier
estimated to be 10–15 Kd heavier. To exclude concerns that the
second band represents a non-speciﬁc interaction with the anti-
Blimp-1 antibody, we immunoprecipitated Blimp-1 from a pre-
boiled SDS lysate, and immunoblotted with the same antibody
(Santa Cruz 6D3, Fig. 1A). Similar results were obtained with a dif-
ferent commercial antibody (Novus, 3H2-E8). We concluded that
the upper band represents a modiﬁed Blimp-1.
Because the observed modiﬁcation in Blimp-1 was too large to
be accounted for by phosphorylation we have examined whether
Blimp-1 was modiﬁed by either ubiquitin or an ubiquitin-like pro-
tein. To identify the modiﬁer we expressed a C-terminal FLAG-
tagged Blimp-1 (Blimp-1-FL) in 293T cells together with a panel
of HA-tagged members of the ubiquitin family. Cells were pulse-la-
beled with 35S-methionine for 30 min and Blimp-1 was recovered
by anti-FLAG immunoprecipitation. A portion of the immunopre-
cipitate was denatured and re-immunoprecipitated with anti-HA.
When expressed in 293T cells Blimp-1-FL yielded two polypeptides
recovered by anti-FLAG immunoprecipitation, reinforcing our con-
clusion that Blimp-1 undergoes post-translation modiﬁcation. The
modiﬁed Blimp-1 was recovered only when HA-SUMO-1 was coex-
pressed (Fig. 1B). Thus, we conclude that Blimp-1 is SUMOylated.
To determine whether Blimp-1 exerts a preference to either of
the SUMO isotypes we coexpressed Blimp-1-FL with an HA-tagged
SUMO-1, 2 or 3 in 293T cells. Fourty-eight hours after transfection,
cell lysates were prepared and Blimp-1-FL was immunoprecipi-
tated with anti-FLAG antibodies and subjected to immunostaining
with anti-HA and anti-FLAG antibodies. Blimp-1 exerted a strong
preference for HA-tagged SUMO-1 (Fig. 1C). Blimp-1 was also
modiﬁed with endogenous SUMO-1 (Fig. 1D). Taken together we
demonstrate for the ﬁrst time the SUMOylation of Blimp-1 with
SUMO-1.
Next, we wanted to compare the turnover of unmodiﬁed Blimp-
1 to the SUMOylated form (Blimp-1-SUMO). We transfected 293T
cells with Blimp-1-FL. Twenty-four hours after transfection the
cells were pulse-labeled with 35S-methionine for different time
periods. Autoradiography analysis of the immunoprecipitates
showed that SUMOylation was clearly discerned after 10 min
pulse. Interestingly, as the pulse period increased the level of
Blimp-1 increased more than Blimp-1-SUMO, suggesting that the
modiﬁcation is removed (Fig. 1E). To test this possibility we per-
formed a pulse-chase analysis. The unmodiﬁed Blimp-1 was rela-
tively stable, while Blimp-1-SUMO decayed during this time
(Fig. 1F). Our data show that in 293T cells the modiﬁcation of
Blimp-1 with SUMO-1 occurs rapidly after synthesis.
Blimp-1 contains several sequences of the consensus SUMOyla-
tion motifs (for a list of putative SUMOylation sites and their calcu-
lated score see Fig. S2). However, in almost half of the proteins
SUMOylation occurs on non-motif residues [16]. To map the
SUMOylation sites on Blimp-1 we individually mutated to arginine
all consensus lysines with high scores. All mutants exhibited
SUMOylation (not shown) suggesting that Blimp-1 is most likely
SUMOylated on non-canonical sites.
3.2. SENP1 regulates Blimp-1 SUMOylation
Of the different SUMOproteases, only SENP1 is speciﬁc to SUMO-
1 [17,18]. To testwhether SENP1 is able to deSUMOylate Blimp-1we
expressed a FLAG-tagged version of either active SENP1 (FL-SENP1)
or a catalytically dead mutant with dominant negative activity (FL-
SENP-1-DN). These constructs when overexpressed diminish or in-
crease the total SUMOylation level, respectively (Fig. 2A). SENP1 or
its DN version were expressed together with Blimp-1 and HA-
SUMO-1. Cells were pulse-labeled and chased for 1 h and lysates
thereof were immunoprecipitated with anti-FLAG. The expression
Fig. 1. Blimp-1 undergoes reversible SUMOylation with SUMO-1. (A) Nuclear extract was prepared from P3X plasmacytoma cells. A portion of the extract was boiled in 1%
SDS, diluted in NP40 lysis buffer and immunoprecipitated with anti-Blimp-1 antibody. Following Western blot analysis, membranes were stained with the same antibody. (B)
293T cells were cotransfected with Blimp-1-FL and HA-tagged ubiquitin or ubiquitin like protein. Cells were pulsed labeled for 30 min with 35S-methionine. Cells were lyzed
in 1% SDS and diluted in lysis buffer. Blimp-1 was immunoprecipitated with anti-FLAG. Immunoprecipitates were boiled in 1% SDS supplemented with 5 mM DTT, diluted in
lysis buffer and re-immunoprecipitated with anti-HA, before being analyzed by SDS-PAGE. (C) 293T cells were cotransfected with Blimp-1-FL and HA-SUMO-1, 2 or 3.
Extracts were made in 1% SDS. A portion was analyzed by SDS-PAGE while the rest of the lysate was diluted in lysis buffer and immunoprecipitated with anti-FLAG.
Immunoprecipitates were analyzed by Western blotting with anti-FLAG or anti-HA antibodies. (D) 293T cells were transfected with Blimp-1-FL. Total cells extract was
immunoprecipitated with anti-FLAG and blotted with anti-FLAG and anti-SUMO1. (E) 293T cells were transfected with Blimp-1-FL. Cells were pulse-labeled with 35S-
methionine for the indicated time. Lysates were prepared in 1% SDS, diluted with lysis buffer and immunoprecipitated with anti-FLAG beads. (F) Cells were pulse-labeled with
35S-methionine for 30 min and chased up to 4 h. Lysates were prepared and analyzed as in D. Shown are typical experiments of three independent repetitions.
Fig. 2. SUMOylation of Blimp-1 is modulated by SENP1. (A) 293T cells were transfected with either wt FL-SENP1 or inactive FL-SENP1-DN. Total cell extract was
immunoblotted with anti-SUMO1. (B) 293T cells were cotransfected with Blimp-1-FL, HA-SUMO-1 and either wt FL-SENP1 or inactive FL-SENP1-DN. Cells were pulse-labeled
for 30 min and chased for 1 h. Cells were lyzed followed by immunoprecipitated with anti-FLAG. Immunoprecipitates were analyzed by SDS–PAGE followed by
autoradiography. (C) Cells were cotransfected as in A, lyzed and lysates were immunoprecipitated with anti-FLAG. Immunoprecipitates were analyzed by Western blotting
with anti-FLAG and anti-HA to detect Blimp-1 and Blimp-1-SUMO, respectively.
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expression of FL-SENP-1-DN augmented the level of SUMOylation.
At the 1 h chase time we observed additional polypeptides heavier
than Blimp-1-SUMO, suggesting the addition of multiple SUMO
molecules to a single Blimp-1 (Fig. 2B). When analyzed by Westernblotting, overexpression of SENP1 diminished Blimp-1-SUMO lev-
els. Enhancement in Blimp-1 SUMOylation was robustly seen when
SENP-1-DN was expressed (Fig. 2C). The fact that SENP1-DN in-
creases Blimp-1 SUMOylation indicates that endogenous SENP-1
activity restricts the accumulation of SUMOylated Blimp-1.
Fig. 3. SENP1 controls the turnover of Blimp-1. (A) 293T cells were cotransfected with SUMO-Blimp-1-FL and SUMO-GST-FL. Cells were pulsed labeled for 30 min with 35S-
methionine and chased up to 4 h in the presence and absence of MG132. Cells were lyzed and immunoprecipitated with anti-FLAG as mentioned in Fig. 1. Immunoprecipitates
were analyzed by SDS–PAGE. Shown is a typical experiment of three independent repetitions. (B) 293T cells were cotransfected with Blimp-1-FL and FL-SENP1-DN. Cells were
pulsed labeled for 30 min with 35S-methionine and chased up to 4 h, lyzed and immunoprecipitated with anti-FLAG as mentioned in Fig. 1. Immunoprecipitates were
analyzed by SDS–PAGE. Shown is a typical experiment and its densitometry quantiﬁcation. (C) HeLa and MEFs cells were transfected either with Blimp-1-FL alone or
cotransfected with Blimp-1-FL and FL-SENP1 at a 1:4 ratio. Cells were pulse-chased, lysed and subjected to immunoprecipitation as described before. Shown is a typical
experiment and densitometry quantiﬁcation of three independent experiments. Bars represent S.D. Both modiﬁed and non-modiﬁed Blimp-1 were taken into account in the
quantiﬁcation. Statistical signiﬁcance (Mann–Whitney, p < 0.05) is indicated by ⁄. (D) Splenic B cells were isolated by CD43 depletion. Cells were treated for 3 days with LPS
and subjected to pulse-chase analysis in the presence or absence of MG132 (25 lM). Lysates were immunoprecipitated with rat anti-Blimp-1 and immunoprecipitates were
analyzed by SDS–PAGE. Shown is a typical experiment of three repetitions. Bands intensity were quantiﬁed by densitometry. Statistical signiﬁcance (Mann–Whitney,
p < 0.05) is indicated by ⁄. (E) P3X cells were stably transformed with pBABE-puro or shRNA to SENP1 which contains puromycin selection. Following selection with
puromycin (3 lg/ml) cells were pulsed labeled for 30 min with 35S-methionine and chased up to 4 h, lyzed and immunoprecipitated with anti-Blimp-1 as mentioned in D.
Immunoprecipitates were analyzed by SDS–PAGE. Shown is a typical experiment and its densitometry quantiﬁcation of three independent repetitions. Statistical signiﬁcance
(Mann–Whitney, p < 0.05) is indicated by ⁄.
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When DN-SENP1 was coexpressed with Blimp-1 and SUMO-1
we observed a smear in a molecular weight higher than SUMO-
Blimp-1 (Fig. 2C). We suspected that this may represent ubiquiti-
nation of the SUMO-Blimp-1 adduct. We were not able to directly
demonstrate Blimp-1 modiﬁcation with endogenous ubiquitin.
Nonetheless, we decided to test whether SUMOylation of Blimp-1
serves as a signal for proteasomal degradation. To this end we
fused HA-SUMO-1 to the N-terminus of Blimp-1. To render the
fusion protein impervious to SUMO proteases we deleted the
terminal diglycine residues. As control we employed the same
modiﬁcation to glutathione S-transferase (GST), a stable protein.
HA-SUMO-1(-GG)-Blimp-1-FL and HA-SUMO-1(-GG)-GST-FL were
cotransfected to 293T cells and subjected to pulse-chase analysis.
While the GST fusion was stable, Blimp-1 when fused to SUMO-1
underwent rapid degradation which was inhibited by inclusion of
a proteasome inhibitor (Fig. 3A). These results suggest that
SUMO-1 serves a speciﬁc signal for Blimp-1 degradation. We
hypothesized that Blimp-1 is stable in 293T cells owing to, at least
in part, high activity of SENP1. Therefore, we measured the stabil-ity of Blimp-1 in the presence of FL-SENP-1-DN. In accord with this
hypothesis Blimp-1 was degraded faster in the presence of FL-
SENP-1-DN (Fig. 3B). In contrast to 293T cells, Blimp-1 is labile in
HeLa and MEFs cells. In this case we wanted to test whether
expression of SENP1 can rescue Blimp-1 from degradation.
Blimp-1 was coexpressed with SENP1-FL or an empty vector and
Blimp-1 turnover was measured by pulse-chase analysis. Indeed,
under overexpression conditions, SENP1 expression decreased
Blimp-1 degradation (Fig. 3C).
In all of the previous studies we examined an exogenously ex-
pressed Blimp-1. To monitor the stability of endogenous Blimp-1
we used two cell systems: day 3 LPS-activated primary B cells
and the plasmacytoma cell line P3X. We observed that in primary
B cells Blimp-1 underwent proteasomal degradation, as inclusion
of the proteasome inhibitor MG132 increased the recovery of the
protein (Fig. 3D). To examine the role of SENP1 in the stability of
Blimp-1 we knocked-down SENP1 in P3X cells by shRNA. The efﬁ-
ciency of knock-down was assessed by immunoblot to SENP1
(Fig. S1). We observed that Blimp-1 degradation was enhanced in
the knocked down cells (Fig. 3E). These data underscore SENP1
as a modulator of Blimp-1 stability.
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Modiﬁcation with SUMO occurs on both transcription activators
and repressors. While SUMOylation of transcription activators is
invariably associated with attenuation of activity [19], SUMOyla-
tion of repressors yields a diverse phenotype that may either en-
hance or decrease the repression activity [20].
SUMOylation of Krueppel-like factors seems to be a common
post-translation modiﬁcation. Krueppel-like factor 8 (KLF8) is
modiﬁed on a single lysine by SUMO-1, 2 and 3 in a process cata-
lyzed by SUMO E3 ligases [21]. KLF1 may act as a transcription
repressor or activator. KLF1 SUMOylation is not important for its
transcription activation, while being absolutely essential for gene
repression [22]. SUMOylation of HIC1 was also required for its
transcription repression activity [23]. Thus, the fact that Blimp-1
undergoes SUMOylation is not unusual. We found that Blimp-1 is
rapidly and exclusively modiﬁed with SUMO-1 (Fig. 1). However,
while the SUMOylation of the other Krueppel-like factors is stably
discerned in the nucleus, Blimp-1 was recovered from nuclear ex-
tracts largely in its unmodiﬁed form (not shown). Thus, Blimp-1
SUMOylation may not play a direct role in its interaction with
the DNA. Because of transient nature of Blimp-1 SUMOylation we
did not address its role in transcription, rather in modulating
Blimp-1 stability.
The crosstalk between the SUMO and ubiquitin machineries is
poorly understood. In mammalian cells, RNF4 is an E3 ubiquitin li-
gase which utilizes a SUMO-interacting domain (SIM) as a recogni-
tion element. Thus, RNF4 ubiquitinates SUMOylated substrates.
However, RNF4 has a preference for substrates decorated with
multiple SUMO-2 rather than a single SUMO-1, such as the PML
protein [24]. Using a knock-down approach we excluded the
involvement of RNF4 in Blimp-1 degradation (not shown). Further-
more, our data infer that the underlying E3 ligase is speciﬁc to the
SUMO-Blimp-1 conjugate rather than only recognizing the SUMO-
1 moiety (Fig. 3). Hence, we suspect the involvement of a novel E3
ligase in Blimp-1 turnover, which most likely has higher afﬁnity to
the SUMO conjugate.
Because Blimp-1 SUMOylation is regulated by SENP1 activity
(Fig. 2), we postulated that SENP1 would protect Blimp-1 from pro-
teasomal degradation. Indeed, Blimp-1 is subjected to a basal slow
rate of proteasomal turnover in plasma cells (Fig. 3D) and SENP1
activity can be manipulated to regulate its levels (Fig. 3B–D). Our
data identiﬁes for ﬁrst time regulation of Blimp-1 at a post tran-
scription level, which may be relevant to control its levels in nor-
mal and in transformed PCs.
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